A 9-year-old spayed female Miniature Poodle presents with...

Thank you for reaching out, doctor. This is an excellent case presentation, and your suspicion of hyperadrenocorticism (HAC) in this 9-year-old Miniature Poodle is well-founded. The signalment (older Miniature Poodle), classic clinical signs (pot-bellied, symmetrical truncal alopecia, PU/PD), and supporting laboratory abnormalities (significantly elevated ALP, stress leukogram, dilute urine specific gravity of 1.015) all point strongly towards this diagnosis.

While other differentials for PU/PD and elevated ALP exist (e.g., diabetes mellitus, chronic kidney disease, primary liver disease, pyometra if intact), the constellation of signs in this patient makes HAC the leading differential.

For the most appropriate initial diagnostic test to confirm suspected hyperadrenocorticism in this patient, I would recommend a Low-Dose Dexamethasone Suppression Test (LDDST).

Here's my reasoning:

Sensitivity and Specificity: The LDDST is generally considered the gold standard screening test for diagnosing spontaneous hyperadrenocorticism. It boasts a sensitivity of approximately 85-100% and a specificity of 50-75% for HAC. This makes it superior to the ACTH stimulation test for initial diagnosis, as the ACTH stim can miss up to 15-20% of pituitary-dependent hyperadrenocorticism (PDH) cases.

Ruling in vs. Ruling out: While a urine cortisol:creatinine ratio (UCCR) is a highly sensitive screening test (excellent for ruling out HAC if negative), an elevated UCCR (which is likely in this patient given the strong clinical picture) would still necessitate further testing with an LDDST or ACTH stimulation test to confirm the diagnosis. Given the high index of suspicion here, proceeding directly to an LDDST is often the most efficient and definitive first step.

Initial Differentiation Potential: Beyond simply diagnosing HAC, the LDDST can also provide preliminary information to help differentiate between pituitary-dependent hyperadrenocorticism (PDH) and adrenal-dependent hyperadrenocorticism (ADH). While not definitive for differentiation, the pattern of suppression can be suggestive.

Procedure for Low-Dose Dexamethasone Suppression Test:

Baseline Cortisol Sample: Collect a blood sample for a baseline serum cortisol concentration.

Dexamethasone Administration: Administer dexamethasone (dexamethasone sodium phosphate or dexamethasone solution) intravenously at a dose of 0.01 mg/kg.

Post-Dexamethasone Cortisol Samples: Collect additional blood samples for serum cortisol concentration at 4 hours and 8 hours post-dexamethasone administration.

Interpretation:

* Normal Patient: Serum cortisol concentrations at both 4 and 8 hours post-dexamethasone should be suppressed (typically <1.4 µg/dL or <40 nmol/L, though laboratory specific cut-offs may vary).
* Diagnosis of Hyperadrenocorticism: If the 8-hour post-dexamethasone cortisol concentration fails to suppress (i.e., remains above the laboratory's suppression cut-off, often >1.4 µg/dL), hyperadrenocorticism is confirmed.
* Suggestive of PDH: If the 4-hour post-dexamethasone cortisol concentration suppresses (e.g., <1.4 µg/dL or <50% of baseline), but the 8-hour sample fails to suppress, this pattern is highly suggestive of PDH.
* Suggestive of ADH: If there is no suppression at either the 4-hour or 8-hour mark, it could indicate ADH or a non-suppressing PDH.

Next Steps (if HAC is confirmed):

Should the LDDST confirm hyperadrenocorticism, the next step would be to definitively differentiate between PDH and ADH, as this dictates treatment. This typically involves:

* Abdominal Ultrasound: To evaluate the adrenal glands (size, symmetry, presence of a mass).
* Endogenous ACTH Concentration: A high or normal endogenous ACTH level suggests PDH, while a low or undetectable level suggests ADH.

I have high confidence that the LDDST is the most appropriate initial diagnostic test here, providing the best balance of sensitivity and information yield for this patient. Please ensure the patient is otherwise stable and not concurrently ill with non-adrenal illness, as severe concurrent illness can sometimes lead to false positive results.